Cairo Mitchell S, Raetz Elizabeth, Lim Megan S, Davenport Virginia, Perkins Sherrie L
Department of Pediatrics, Columbia University, New York, NY 10032, USA.
Pediatr Blood Cancer. 2005 Nov;45(6):753-69. doi: 10.1002/pbc.20342.
Pediatric non-Hodgkin lymphoma (NHL) is a common and fascinating group of diseases with distinctive underlying genetic events that characterize the major histologic subtypes: diffuse large B-cell lymphoma, Burkitt lymphoma, anaplastic large cell lymphoma and lymphoblastic lymphoma. With systematic improvements in therapy over recent decades, the vast majority of children with NHL of all subtypes are now cured. The similarities and differences between adult and childhood presentations of disease, and whether or not some subtypes of NHL and leukemia are the same or different disease entities, are interesting questions that will be addressed with advances in our understanding of the molecular and genetic bases of these diseases. As is the case with other pediatric malignancies, growing emphasis is now being placed on the development of less toxic, targeted therapeutic approaches, and this review highlights some of the biological discoveries that will potentially open these avenues.
小儿非霍奇金淋巴瘤（NHL）是一组常见且引人关注的疾病，具有独特的潜在遗传事件，这些事件是主要组织学亚型的特征：弥漫性大B细胞淋巴瘤、伯基特淋巴瘤、间变性大细胞淋巴瘤和淋巴细胞性淋巴瘤。近几十年来，随着治疗方法的系统性改进，绝大多数各亚型小儿NHL患儿现已治愈。成人和儿童疾病表现之间的异同，以及某些NHL亚型和白血病是否为相同或不同的疾病实体，都是有趣的问题，随着我们对这些疾病分子和遗传基础认识的进步将会得到解答。与其他小儿恶性肿瘤一样，现在越来越强调开发毒性较小的靶向治疗方法，本综述重点介绍了一些可能开辟这些途径的生物学发现。
